Fig. 4.

CBSC + CTRP9-281 exerts greater synergetic cardioprotection superior to CBSC + gCTRP9. A/B: Representative echocardiographic images (A = M mode, B=B mode) 6 weeks after MI. Three-dimensional regional wall strain diagrams showing contraction (orange/positive values) or relaxation (blue/negative values) of 3 consecutive cardiac cycles. C: Strain analysis results of long-axis B-mode images. n = 10–12/group. *P < 0.05, **P < 0.01. D: Survival curves (n = 12/group for sham and 27-45/group for MI). *P < 0.05, **P < 0.01. E: Left ventricular ejection fraction (LVEF), n = 10–18/group**P < 0.01. F: Heart weight/body weight ratio (HW/BW). *P < 0.05, **P < 0.01. G: Lung weight/body weight ratio (LW/BW), n = 10–18. *P < 0.05, **P < 0.01. Survival curves were analyzed by Gehan-Breslow-Wilcoxon test. LVEF were analyzed with 2-way ANOVA followed by a Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)